Neoplasia/BPH

	Preoperative prediction of pathological pelvic lymph node metastasis in prostate cancer using an elastic net model integrating clinicopathologic and (68)Ga-PSMA PET/CT features: development and temporal validation. Sci Rep Chen Y, Gao L, Zheng Z, Feng P, Zhang C, Shi G, Li S, Hu J, Wang L, Wu B, Cao X. PMID: 42270733 [PubMed - as supplied by publisher]
	Comment on 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'. BJU Int Urolagin D, Sowmya BA, Kavyashree MV. PMID: 42269719 [PubMed - as supplied by publisher]
	Effect of [(68)Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial. Lancet Oncol Buteau JP, Moon D, Fahey MT, Roberts MJ, Ayati N, Papa N, Murphy DG, Kasivisvanathan V, Dhillon HM, Du YT, Dundee P, Foudoulis J, Hennes D, Hutton AC, Idiare J, Jack G, Kamath S, Lee SN, Lee SF, Lee ST, Leslie S, Levy SM, Link E, Mitchell C, Morigi JJ, Nguyen A, Olphert J, Patel MI, Pattison DA, Pearce A, Perera M, Thanigasalam R, Thomson A, Yaxley J, Thompson J, Hofman MS, Emmett L, PRIMARY2 Trial Investigators. PMID: 42269655 [PubMed - as supplied by publisher]
	Cell-free DNA in prostate cancer and treatment selection. Expert Rev Anticancer Ther McKendry K, Maurice-Dror C, Chi KN. PMID: 42269177 [PubMed - as supplied by publisher]
	Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity. J Urol George A, Giesler E, Mazzarella B, Levin R, Frendl D, Warlick C, Given R, Kella N, Frye T, Mynderse L, Kasraeian A, Milbank A, Nabbout P, Grunberger I, Rastinehad A, Schwartz M, Wysock J, Rousseau M, Pliskin M, Satkunasivam R, Rich D, Shore ND, Moreno J, Belkoff L, Sidana A, Taneja SS. PMID: 42269147 [PubMed - as supplied by publisher]
	Influence of Artificial Intelligence Assistance on Gleason Grading and Prostate Cancer Detection by Uropathologists in Daily Practice: A Prospective Multicenter Study. JCO Clin Cancer Inform van Hees JE, van Diest PJ, Nguyen TQ, Lynch MG, Jonges TN, Meijer RP, Willemse PM, Suelmann BBM, van Dooijeweert C. PMID: 42269140 [PubMed - in process]
	Change in Adherence to Oral Antidiabetic Medications Before and After Prostate Cancer Diagnosis: A Group-Based Trajectory Modeling Approach. Clin Drug Investig Kenawy AS, Baffoe JO, Park C. PMID: 42268571 [PubMed - as supplied by publisher]
	Identifying PLAU as a shared pathogenic gene in type 2 diabetes and bladder urothelial carcinoma through integrated transcriptomic analysis and machine learning for diagnostic and therapeutic value. Clin Exp Med Xin S, Li G, Yang X, Su J, Li R, Qin W, Zhang Z, Wang C, Zhu Y, Feng L, Ren S, Gao Z. PMID: 42268472 [PubMed - as supplied by publisher]
	Deep spatial proteomics reveals a suppressive immune niche linked to immune evasion in renal cell carcinoma. Cancer Drug Resist Zhang Y, Zhu Y, Liu Z, Li H, Zhong B, Cui X, Kong Y, Lu H. PMID: 42267194 [PubMed]
	Global landscape analysis of antibody-drug conjugate clinical trials for prostatic neoplasms: current status, opportunities and challenges. Front Immunol Ren S, Pan F, Jin J. PMID: 42266702 [PubMed - in process]
	The international and domestic research trends of targeted therapy in bladder cancer: a bibliometric analysis of the past three decades. Front Oncol Pan Y, Sun Y, Jiao B, Zhang Y, Zhang G. PMID: 42266656 [PubMed]
	Self-Management Experience of Chinese Patients With Nonmuscle-Invasive Bladder Cancer During Intravesical Therapy: A Qualitative Study. Cancer Nurs Deng C, Soivong P, Akkadechanunt T, Sethabouppha H. PMID: 42266078 [PubMed - as supplied by publisher]
	A Nomogram for Predicting 28-Day Mortality in Critically Ill Patients With Prostate Cancer: A Retrospective Cohort Study Based on the MIMIC-IV Database. Arch Esp Urol Yao Y, Dong J, Wang Z, Su Y. PMID: 42265963 [PubMed - in process]
	A Retrospective Follow-up Study on the Effects of Different Intravesical Treatments on Recurrence Control and Quality of Life in Patients With Non-Muscle-Invasive Bladder Cancer After Transurethral Resection of Bladder Tumour. Arch Esp Urol Liu F, Hu X, Zhu X, Han T, Feng L. PMID: 42265962 [PubMed - in process]
	Association Between Functional Multiparametric MRI Features and Tumour Immune Microenvironment Phenotypes in Prostate Cancer: A Retrospective Study. Arch Esp Urol Wang P, Wang E, Ji G, Deng H, Yuan Y, Lin X, Chen K, Xiao S, Liu F. PMID: 42265960 [PubMed - in process]
	Proton Beam Therapy in Prostate Cancer: Clinical Evidence, Controversies and Future Directions. Arch Esp Urol Gomis-Sellés E, González de Dueñas M, Meca G, García-Marqueta M, Moreno-López S, Albendea Roch J, Garrido Botella MI, Caballero B, Gómez Rivas J, Shelan M, López Campos F, Couñago F. PMID: 42265951 [PubMed - in process]
	The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study. BJU Int Cheng HH, Maxwell KN, Salari K, Cooperberg MR, Follmer K, Jeter JM, Jun G, Lee DJ, Patel HD, Schaeffer EM, Sokolova AO, Wolff EM, Lin DW. PMID: 42265755 [PubMed - as supplied by publisher]
	Response letter 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'. BJU Int van Hattum JW, Remmelink MJ, Oddens JR, de Reijke TM, Wilmink HW. PMID: 42265552 [PubMed - as supplied by publisher]
	Optimizing testicular cancer therapy: Survivorship perspectives on reducing late toxicities without compromising outcomes. Urol Oncol Cheng KW, Castillo JK, Douglawi A, Hofmann M, Ruckle HC, Prakash G, Hu B, Alsyouf M. PMID: 42265043 [PubMed - as supplied by publisher]
	Re: Brian F. Chapin, Marc Smaldone, Amado J. Zurita, et al. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. Eur Urol. In Press. http://dx.doi.org/10.1016/j.eururo.2026.02.011. Eur Urol Froehner M. PMID: 42265042 [PubMed - as supplied by publisher]

Articles 1 - 20 / 188466

Page 1 of 9424



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy